Enact Holdings Inc

NASDAQ: ACT
$29.48
+$0.20 (+0.7%)
Closing price April 18, 2024
Enact Holdings, Inc. operates as a private mortgage insurance company in the United States. The company engages in writing and assuming residential mortgage guaranty insurance. It also offers private mortgage insurance products primarily insuring prime-based, individually underwritten residential mortgage loans; and contract underwriting services for mortgage lenders. It primarily serves residential mortgage loan originators. The company was formerly known as Genworth Mortgage Holdings, Inc. and changed its name to Enact Holdings, Inc. in May 2021. Enact Holdings, Inc. was founded in 1981 and is headquartered in Raleigh, North Carolina. Enact Holdings, Inc. operates as a subsidiary of Genworth Holdings Inc.
Botox maker Allergan has entered a definitive agreement to be acquired by Actavis, despite higher offer from Valeant Pharmaceuticals.
A new Deutsche Bank report from the firm's quantitative strategies team highlights the current best buy ideas.
The analysts at Piper Jaffray are very positive on four top specialty pharmaceutical stocks with potential for a strong fourth-quarter rally in their shares.
A new research report from Merrill Lynch features three top pharmaceutical companies, dubbed the “Irish 3-Pack.”
Source: Jon OggStocks were holding on to small gains on Tuesday even after weaker sentiment was reported out of Europe. It looks as though investors have decided they can now shop around for stocks...
These are the top analyst upgrades, downgrades and initiations from Wall Street firms for Friday, June 27, 2014. They include Alcoa, Cigna, Intel, Molina Healthcare, Teva Pharmaceutical and...
Source: ThinkstockThere are 84 stocks in the Standard & Poor’s 500 Index which trade for more than $100 a share. The best known are Google Inc. (NASDAQ: GOOG) and Apple Inc. (NASDAQ: AAPL),...
Two analyst upgrades on Friday, a new CEO and a 33% increase in its stock price since November may be confirmation that Teva Pharmaceutical Industries is finally rebounding. Analysts think the stock...
The biotech and specialty pharmaceutical groups got hit hard Thursday for a variety of reasons. The largest of which the analysts at Jefferies believe, is commentary within Washington's new budget...
These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on Wednesday February 19, 2014. They include Analog Devices, Chelsea Therapeutics, Tesla Motors and...
Source: thinkstockFebruary 18, 2014: Markets opened slightly higher on Monday but the DJIA turned south quickly and struggled all day before finishing with a fractional loss. The healthcare sector,...
Source: Frank Golhen, via Wikimedia CommonsAt the beginning of the year, we presented the lists from most major Wall Street firms of their top stocks to buy for the year. After one of the biggest and...
U.S. equity markets opened mixed this morning and failed to find a direction driver throughout the trading day. In Europe, Germany reported a stronger-than-expected trade surplus, while the U.K.’s...
The negative fourth-quarter gross domestic product (GDP) reading of -0.1% caught most Wall St. analysts and economists by surprise. This unforeseen number was skewed by a huge decrease in government...